Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the Hits-c study

White, B.; Dore, G.J.; Lloyd, A.R.; Rawlinson, W.D.; Maher, L.

The Medical Journal of Australia 201(6): 326-329


DOI: 10.5694/mja13.00153
Accession: 068511956

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

To estimate hepatitis C virus (HCV) incidence and identify associated risk and protective factors among people who inject drugs (PWID) in Sydney, New South Wales. Community-based prospective observational study of serologically confirmed HCV antibody-negative PWID enrolled in six Sydney neighbourhoods located in three distinct regions between 10 November 2008 and 31 October 2011. Serologically confirmed HCV incidence per person-years (py); and self-reported demographic and behavioural risk factors for HCV infection. The overall incidence of HCV infection was 7.9/100 py. Risk factors independently associated with incident HCV infection were younger age (adjusted hazard ratio [AHR] for age < 27 years, 5.66; 95% CI, 1.69-18.95; P = 0.005) and daily or more frequent injecting (AHR, 4.06; 95% CI, 1.15-14.30; P = 0.03). Opioid substitution therapy (OST) was protective against HCV seroconversion and was associated with a reduced risk of incident infection among those who mainly injected heroin or other opioids (AHR for those not receiving OST while mainly injecting heroin or other opioids, 5.64; 95% CI, 1.30-24.42; P = 0.02). The observed HCV incidence was substantially lower than the incidence of 30.8/100 py observed a decade earlier in a similar NSW-based cohort, suggesting a decline in HCV incidence among PWID. This is likely due to increased coverage of OST, combined with a probable decrease in the population of PWID.